Back to Stories
PxWire Volume 14, Issue No. 4
Check out the latest issue of PxWire here! And see key highlights below:
- Since 2019, rates of HIV acquisition in Latin America have been trending upward. At the same time, Latin America has taken strides to combat this trend, from increasing PrEP initiation rates to preparing for longer acting PrEP products.
- On October 2, Gilead Sciences announced six licenses to generic manufacturers in Egypt, India, and Pakistan to produce and market lenacapavir for PrEP in 120 countries.
- Generic regulatory approval submission for LEN for PrEP may begin as early as the second half off 2026, two years after Gilead announced positive trial results.
- Launched at HIVR4P 2024, the People’s Research Agenda is a collaboratively developed framework for aligning the needs and priorities of affected communities with the agenda for HIV prevention research.